ATE332138T1 - Flibanserin zur behandlung extrapyramidaler bewegungsstörungen - Google Patents

Flibanserin zur behandlung extrapyramidaler bewegungsstörungen

Info

Publication number
ATE332138T1
ATE332138T1 AT01111195T AT01111195T ATE332138T1 AT E332138 T1 ATE332138 T1 AT E332138T1 AT 01111195 T AT01111195 T AT 01111195T AT 01111195 T AT01111195 T AT 01111195T AT E332138 T1 ATE332138 T1 AT E332138T1
Authority
AT
Austria
Prior art keywords
parkinson
disease
treatment
extrapyramidal
idiopathic
Prior art date
Application number
AT01111195T
Other languages
English (en)
Inventor
Juergen K Dr Beck
Original Assignee
Juergen K Dr Beck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juergen K Dr Beck filed Critical Juergen K Dr Beck
Application granted granted Critical
Publication of ATE332138T1 publication Critical patent/ATE332138T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01111195T 2001-05-11 2001-05-11 Flibanserin zur behandlung extrapyramidaler bewegungsstörungen ATE332138T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111195A EP1256343B1 (de) 2001-05-11 2001-05-11 Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen

Publications (1)

Publication Number Publication Date
ATE332138T1 true ATE332138T1 (de) 2006-07-15

Family

ID=8177363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01111195T ATE332138T1 (de) 2001-05-11 2001-05-11 Flibanserin zur behandlung extrapyramidaler bewegungsstörungen

Country Status (12)

Country Link
US (1) US8030314B2 (de)
EP (1) EP1256343B1 (de)
JP (1) JP4634008B2 (de)
AT (1) ATE332138T1 (de)
AU (1) AU2002310813B2 (de)
CA (1) CA2444062C (de)
CY (1) CY1105648T1 (de)
DE (1) DE60121301T2 (de)
DK (1) DK1256343T3 (de)
ES (1) ES2267627T3 (de)
PT (1) PT1256343E (de)
WO (1) WO2002092088A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
JP2006516549A (ja) * 2002-12-23 2006-07-06 メルク フロスト カナダ アンド カンパニー パーキンソン病の治療用医薬組成物及び治療方法
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (de) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Verfahren zur behandlung von aufmerksamkeitsdefizitstörung mit hyperaktivität
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1858516A1 (de) * 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmazeutische zusammensetzungen zur behandlung und/oder verhinderung von depressionen
US20060199805A1 (en) * 2005-03-04 2006-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
EP1904182A2 (de) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Verfahren zur behandlung von drogenmissbrauch mit flibanserin
JP2008540672A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 病状に起因する性的機能不全の治療方法
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP1988898A2 (de) * 2006-02-18 2008-11-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzungen mit flibanserin zur behandlung von aufmerksamkeitsdefizitstörung mit hyperaktivität
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20090312242A1 (en) * 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2056797A2 (de) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH System mit kontrollierter freisetzung und verfahren zu seiner herstellung
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0942732B1 (de) * 1996-12-02 2004-11-17 MERCK SHARP & DOHME LTD. Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
FR2768338B1 (fr) * 1997-09-17 1999-10-15 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la monoamine oxydase et leur application en therapeutique

Also Published As

Publication number Publication date
CA2444062C (en) 2011-02-22
AU2002310813B2 (en) 2008-04-03
EP1256343A1 (de) 2002-11-13
CA2444062A1 (en) 2002-11-21
DE60121301T2 (de) 2007-07-19
JP2004529175A (ja) 2004-09-24
CY1105648T1 (el) 2010-12-22
WO2002092088A3 (en) 2003-01-30
US20040180904A1 (en) 2004-09-16
DK1256343T3 (da) 2006-10-30
EP1256343B1 (de) 2006-07-05
PT1256343E (pt) 2006-11-30
ES2267627T3 (es) 2007-03-16
DE60121301D1 (de) 2006-08-17
WO2002092088A2 (en) 2002-11-21
JP4634008B2 (ja) 2011-02-16
US8030314B2 (en) 2011-10-04

Similar Documents

Publication Publication Date Title
ATE332138T1 (de) Flibanserin zur behandlung extrapyramidaler bewegungsstörungen
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
JP4219399B2 (ja) 分散性錠剤
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
PT1256340E (pt) Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CO5060477A1 (es) Forma de dosificacion de nefazodona
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
EA200600782A1 (ru) Терапевтические применения вариантов хемокинов
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
CA2455621A1 (en) Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders
SE0001916D0 (sv) Novel formulation
CA2429793A1 (en) Interferon therapeutic effect enhancer
RU2002127006A (ru) Новое применение (r)-(-)-2-[5-(4-фторофенил)-3-пиридилметиламинометил]-хромана и его физиологически приемлемых солей
EA200400348A1 (ru) Цисплатиновые составы пониженной токсичности и способы их применения
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1256343

Country of ref document: EP